ClinicalTrials.gg
CompletedNCT04447898Updated May 31, 2024

Dose Escalation Study Assessing the Safety and Immune Response of PPV-06 Vaccine

A Phase 1 interventional study of PPV-06 10 μg and PPV-06 50 μg in Knee Osteoarthritis, sponsored by Peptinov SAS. Completed at 1 site in France. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2024-05-31.

Sponsored by Peptinov SAS · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 124 studies in Osteoarthritis, Knee with a site in France — 23 open to participants now, 33 under way, 1 of them phase 3. Osteoarthritis, Knee · France.

Enrollment
74th of 86
24 · median 106
Started
2021
with 12 others
Phase 1
5 of 124
none open now
Registered
70th of 124
by date

Among the 124 studies in Osteoarthritis, Knee with a site in France, this one is the 74th largest by enrollment of the 86 interventional ones that give a count, is one of 13 that started in 2021, is one of 5 in phase 1, and was the 70th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

23 of the 124 studies in Osteoarthritis, Knee with a site in France are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 124 studies in Osteoarthritis, Knee with a site in France, or all of them as a file.
02

Study summary

PPV-06 immunotherapy targets interleukin-6 (IL-6), a key molecule of the immune system whose overproduction is implicated in many inflammatory and autoimmune diseases such as rheumatoid arthritis and osteoarthritis. The benefit of vaccination with PPV-06 is to induce, in response to immunizations, the production of antibodies directed against IL-6. The antibodies produced will neutralize the biological activity of IL-6 involved in the body's inflammatory process.

The primary objective is to evaluate the safety/tolerability of vaccination with PPV-06.

03

Conditions studied

  • Knee Osteoarthritis
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged over 40 years;
  2. Diagnosis of primary inflammatory Knee Osteoarthritis (KOA),
  3. (BMI) of 18-32 kg/m2 at screening;
  4. Patients with normal organ function at baseline
  5. measures
  6. In the investigator's opinion, the patient is capable and willing to comply with the requirements of the study;
  7. Willing and able to sign a written ;
  8. Affiliated to social security insurance.

Exclusion criteria

Exclusion Criteria:

  1. Systemic or immunodeficiency disease;
  2. Administration of non-steroidal anti-inflammatory drug (NSAID):
  3. Administration of prednisone or having intra-articular injection or bolus intramuscular or intravenous treatment with corticosteroids;
  4. Patients treated with biologics such as anti-TNFAlpha, anti-IL-6 and anti-CD-20
  5. Participation in another drug or vaccine trial;
  6. Knee surgery planned before screening and throughout the study;
  7. Knee surgery within the year of baseline;
  8. Knee trauma within 2 months of baseline;
  9. Chronic and/or C infection. Patients with previous infection, resolved in the past, are eligible;
  10. -positivity;
  11. History of allergic reaction to any constituents of the study drug;
  12. Diagnosis or history of any inflammatory arthritis;
  13. Neurologic disorders involving the lower limbs;
  14. History of within the last 5 years;
  15. Uncontrolled congestive heart failure or hypertension, unstable heart disease
  16. Evidence of any abnormality on a chest X-ray which, in the opinion of the investigator, could represent active infection or latent tuberculosis;
  17. Moderate or severe acute illness/infection, persistent diarrhea or vomiting on the day of vaccination;
  18. Received any licensed, non- within the 14 days before receipt of any dose of the study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of any dose of the study vaccine;
  19. Receipt of immune globulins, blood or blood-derived products;
  20. Pregnant or lactating females;
  21. The investigator considers the patient unfit for the study as a result of the medical interview, physical examination, or screening investigations.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Low dose

    10 μg + Montanide™ ISA 51 VG

    Drug: PPV-06 10 μg · Drug: Placebo

  • Experimental
    High dose

    50 μg + Montanide™ ISA 51 VG

    Drug: PPV-06 50 μg · Drug: Placebo

Interventions

  • DrugPPV-06 10 μg

    Low dose + Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112

  • DrugPPV-06 50 μg

    High dose+ Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112

  • DrugPlacebo

    Placebo+ Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112

06

What researchers measure

Primary outcomes

  1. The proportion of patients with DLT defined as grade 3 or higher treatment-related adverse events (monitored in all patients during the study treatment until the End of Study (Week 42) or early termination).

    The primary outcome measure of this study is to evaluate the safety/tolerability of PPV-06 vaccination

    Time frame: From Baseline to Week 42 (End of Study)

Secondary outcomes

  1. The occurrence of all adverse events (AEs) and serious adverse events (SAEs), including clinically significant abnormal haematological and biochemical values (monitored during the entire study period until End of Study (Week 42) or early termination).

    This secondary outcome measure of this study is to evaluate additional indicators of safety / tolerability

    Time frame: From Baseline to Week 42 (End of Study)

  2. The quantification of inflammatory markers will be assessed at Baseline, W4, W12, W16, W24, W32 and End of Study (Week 42) or early termination by measuring IL-6, hsCRP and CRPM level in blood

    This secondary outcome measure of this study is to evaluate additional indicators of safety / tolerability

    Time frame: From Baseline to Week 42 (End of Study)

  3. The quantification of Anti-IL-6 antibody production, isotypes characterization and anti-CRM197 antibody level in serum at Baseline, W4, W12, W16, W24, W32 and EoS or early termination

    This secondary outcome measure of this study is to evaluate the humoral immune response of PPV-06

    Time frame: From Baseline to Week 42 (End of Study)

  4. The quantification of Anti-IL-6 neutralizing antibody level in vitro at W4, W12, W16, W24, W32 and EoS or early termination

    This secondary outcome measure of this study is to evaluate the humoral immune response of PPV-06

    Time frame: From Baseline to Week 42 (End of Study)

  5. The quantification of specific T cell response and polarization (Th1, Th2 and Th17) assessed by IFNg, IL-5 and IL-17 Elispot assay at Baseline, W24, W32 or early termination.

    This secondary outcome measure of this study is to evaluate the cellular immune response of PPV-06

    Time frame: From Baseline to Week 42 (End of Study)

  6. The quantification of proliferative CD4+T cells assessed by flow cytometry at Baseline, W24, W32 or early termination.

    This secondary outcome measure of this study is to evaluate the cellular immune response of PPV-06

    Time frame: From Baseline to Week 42 (End of Study)

  7. The frequency of hIL-6 epitope-specific memory B cells assessed by ELISPOT assay, at Baseline, W24, W32 or early termination.

    This secondary outcome measure of this study is to evaluate the cellular immune response of PPV-06

    Time frame: From Baseline to Week 42 (End of Study)

07

Study locations

1 site
  • Cic Cochin
    Paris, France
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Feb 2023, 24 months.

Of 34 industry-sponsored phase 1 interventional studies under Osteoarthritis, Knee, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 21. This study's 24 months is above that.

Counting every sponsor, half of 61 studies reached it within 20 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2020
First posted
Jun 25, 2020
StartActual
Feb 18, 2021
Primary completionActual
Feb 28, 2023
CompletionActual
Feb 28, 2023
Last update
May 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04447898
Lead sponsor
Peptinov SAS
Responsible party
Sponsor
First posted
Jun 25, 2020
Start date
Feb 18, 2021
Primary completion
Feb 28, 2023
Completion
Feb 28, 2023
Last update
May 31, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion